search
Back to results

Chronic Effects of DBS in Parkinson's Disease and Dystonia (Activa PC+S)

Primary Purpose

Parkinson's Disease, Isolated Dystonia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Activa PC+S
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Parkinson's Disease focused on measuring deep brain stimulation, cortical recording, neuroprosthesis

Eligibility Criteria

22 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria(both groups):

  • Ability to give informed consent for the study
  • Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria

Inclusion criteria (Isolated dystonia):

  • Age 22-75
  • Isolated dystonia that is generalized or segmental, that must affect one or - Stable doses of anti-dystonia medications (such as Artane, Baclofen, or Clonopin) for at least 30 days prior to baseline assessment
  • For patients with craniofacial involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms.

Inclusion criteria (PD):

  • Age 30-75
  • Bilateral disease (Hoehn and Yahr stage 2 or greater)
  • Has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal tolerated doses as determined by a movement disorders neurologist
  • Stable doses of antiParkinsonian medications for at least 30 days prior to their baseline assessment
  • Significant disability in the setting of optimal medical management by a movement disorders neurologist. Disability may be due to tremor that is unresponsive to medications, or to motor fluctuations
  • UPDRS-III score off medication between 20 and 60
  • Improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score.

Exclusion Criteria (both groups):

  • Pregnancy or breast feeding
  • MRI showing cortical atrophy out of proportion to age
  • MRI showing focal brain lesions that could indicate a non-idiopathic movement disorder,
  • Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin)
  • Inability to comply with study follow-up visits
  • Any prior intracranial surgery
  • Mood depression with a Beck depression inventory score of > 17 on baseline screening
  • Significant cognitive impairment (MoCA<25).
  • History of seizures
  • Immunocompromised
  • Has an active infection
  • Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic - Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.

Sites / Locations

  • UCSF Surgical Movement Disorders Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

chronic brain recording

Arm Description

This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.

Outcomes

Primary Outcome Measures

Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals
To report number of PD patients with reliable cortical and subcortical brain signal recorded using Activa PC+S.

Secondary Outcome Measures

Full Information

First Posted
August 29, 2013
Last Updated
April 4, 2023
Sponsor
University of California, San Francisco
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT01934296
Brief Title
Chronic Effects of DBS in Parkinson's Disease and Dystonia
Acronym
Activa PC+S
Official Title
Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
December 2021 (Actual)
Study Completion Date
December 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Francisco
Collaborators
Medtronic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in movement disorders and how they relate to DBS, not to bring new devices to market.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Isolated Dystonia
Keywords
deep brain stimulation, cortical recording, neuroprosthesis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
chronic brain recording
Arm Type
Experimental
Arm Description
This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
Intervention Type
Device
Intervention Name(s)
Activa PC+S
Intervention Description
Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
Primary Outcome Measure Information:
Title
Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals
Description
To report number of PD patients with reliable cortical and subcortical brain signal recorded using Activa PC+S.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria(both groups): Ability to give informed consent for the study Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria Inclusion criteria (Isolated dystonia): Age 22-75 Isolated dystonia that is generalized or segmental, that must affect one or - Stable doses of anti-dystonia medications (such as Artane, Baclofen, or Clonopin) for at least 30 days prior to baseline assessment For patients with craniofacial involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms. Inclusion criteria (PD): Age 30-75 Bilateral disease (Hoehn and Yahr stage 2 or greater) Has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal tolerated doses as determined by a movement disorders neurologist Stable doses of antiParkinsonian medications for at least 30 days prior to their baseline assessment Significant disability in the setting of optimal medical management by a movement disorders neurologist. Disability may be due to tremor that is unresponsive to medications, or to motor fluctuations UPDRS-III score off medication between 20 and 60 Improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score. Exclusion Criteria (both groups): Pregnancy or breast feeding MRI showing cortical atrophy out of proportion to age MRI showing focal brain lesions that could indicate a non-idiopathic movement disorder, Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin) Inability to comply with study follow-up visits Any prior intracranial surgery Mood depression with a Beck depression inventory score of > 17 on baseline screening Significant cognitive impairment (MoCA<25). History of seizures Immunocompromised Has an active infection Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic - Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Starr, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF Surgical Movement Disorders Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
28409730
Citation
Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Ostrem JL, Galifianakis NB, Luciano MS, Wang SS, Ziman N, Taylor R, Starr PA. Chronic multisite brain recordings from a totally implantable bidirectional neural interface: experience in 5 patients with Parkinson's disease. J Neurosurg. 2018 Feb;128(2):605-616. doi: 10.3171/2016.11.JNS161162. Epub 2017 Apr 14.
Results Reference
result

Learn more about this trial

Chronic Effects of DBS in Parkinson's Disease and Dystonia

We'll reach out to this number within 24 hrs